{"originalText": "结果发_现:术后辅以_RAI_对高危组患者可有生存率获益,对_低危组患者则无此益处;中等强度的_TSH_抑制治疗_(使_TSH_水平保持于正常下限或稍低于正常)可改善_各期别患者生存率;对术后辅以_RAI_的高危患者进行_至少_3_年中等强度_TSH_抑制治疗,可显著改善无病生_存期._在_RAI_抵抗的_DTC_患者(RAI-rDTC)_中进行的_DECISION_前期研究结果显示,索拉非尼可延长无进_展生存期(PFS)._该研究组在本次会议中报告了后续_研究的结果._他们发现:基线资料中的最大肿瘤病灶_大小、病灶数量、甲状腺球蛋白水平以及亚洲地区(相_比欧洲和北美)是决定患者预后的因素,最大肿瘤病_灶<1._5_cm_的患者_PFS_更长,但索拉非尼治疗的获益_似乎低于病灶≥1._5_cm_的患者._病灶≥1._5_cm、肺部_转移是索拉非尼治疗效果更好的预测因子._因此,他_们认为,进展型_RAI-rDTC_和最大肿瘤病灶<1._5_cm_的_患者可能预后较好,", "entities": [{"label_type": "Test", "start_pos": 48, "end_pos": 51}, {"label_type": "Test", "start_pos": 60, "end_pos": 63}, {"label_type": "Test", "start_pos": 122, "end_pos": 125}, {"label_type": "Disease", "start_pos": 154, "end_pos": 157}, {"label_type": "Drug", "start_pos": 194, "end_pos": 198}, {"label_type": "Test", "start_pos": 264, "end_pos": 270}, {"label_type": "Drug", "start_pos": 327, "end_pos": 331}, {"label_type": "Drug", "start_pos": 374, "end_pos": 378}, {"label_type": "Drug", "start_pos": 146, "end_pos": 149}, {"label_type": "Disease", "start_pos": 251, "end_pos": 253}, {"label_type": "Disease", "start_pos": 301, "end_pos": 303}, {"label_type": "Disease", "start_pos": 368, "end_pos": 373}, {"label_type": "Disease", "start_pos": 404, "end_pos": 412}, {"label_type": "Disease", "start_pos": 416, "end_pos": 418}, {"label_type": "Disease", "start_pos": 319, "end_pos": 322}, {"label_type": "Treatment", "start_pos": 11, "end_pos": 14}, {"label_type": "Treatment", "start_pos": 99, "end_pos": 102}]}
{"originalText": "-4_10._58_±_2._16_9._62_±_1._31_10._10_±_1._39_注:略语同图_1_The_abbreviations_are_the_same_as_Fig_1_糖+10-1、10-2、10-3_mmol_/_L_西格列汀组无统计学差异_(P>0._05),脂多糖+10-4_mmol_/_L_西格列汀组胰岛素分_泌量增高(P=0._010)._3._高糖(16._7_mmol_/_L)环境中胰岛素分泌情况:_与对照组相比,_脂多糖组胰岛素分泌增加_(_P_=_0._039),而其他组无统计学差异(P>0._05);与脂多糖_组相比,西格列汀组胰岛素分泌量降低(P_=_0._011),_脂多糖+西格列汀各组胰岛素分泌量无统计学差异_(P>0._05);与西格列汀组相比,脂多糖+10-1、10-2、_10-3_mmol_/_L_西格列汀组无统计学差异(P>0._05),但_脂多糖+10-4_mmol_/_L_西格列汀组胰岛素分泌量增高_(P=0._042)._四、_各组_IL-6_mRNA_表达结果_如图_2_所示,", "entities": [{"label_type": "Drug", "start_pos": 122, "end_pos": 126}, {"label_type": "Drug", "start_pos": 162, "end_pos": 166}, {"label_type": "Drug", "start_pos": 284, "end_pos": 288}, {"label_type": "Drug", "start_pos": 315, "end_pos": 319}, {"label_type": "Drug", "start_pos": 345, "end_pos": 349}, {"label_type": "Drug", "start_pos": 382, "end_pos": 386}, {"label_type": "Drug", "start_pos": 423, "end_pos": 427}, {"label_type": "Test", "start_pos": 167, "end_pos": 174}, {"label_type": "Test", "start_pos": 289, "end_pos": 295}, {"label_type": "Test", "start_pos": 321, "end_pos": 327}, {"label_type": "Test", "start_pos": 428, "end_pos": 434}, {"label_type": "Anatomy", "start_pos": 455, "end_pos": 459}, {"label_type": "Drug", "start_pos": 144, "end_pos": 147}, {"label_type": "Drug", "start_pos": 229, "end_pos": 232}, {"label_type": "Drug", "start_pos": 276, "end_pos": 279}, {"label_type": "Drug", "start_pos": 311, "end_pos": 314}, {"label_type": "Drug", "start_pos": 353, "end_pos": 356}, {"label_type": "Drug", "start_pos": 405, "end_pos": 408}, {"label_type": "Test_Value", "start_pos": 295, "end_pos": 297}, {"label_type": "Test_Value", "start_pos": 238, "end_pos": 240}, {"label_type": "Test_Value", "start_pos": 434, "end_pos": 436}, {"label_type": "Test", "start_pos": 212, "end_pos": 215}, {"label_type": "Test", "start_pos": 233, "end_pos": 236}]}
{"originalText": "随后_与甘精胰岛素组发生率相似._2_组患者均无严重低血_糖事件发生,利拉鲁肽组比甘精胰岛素组轻度低血糖_发生率低,_差异具有统计学意义(4._55%对_21_._43%_,", "entities": [{"label_type": "Drug", "start_pos": 35, "end_pos": 39}, {"label_type": "Drug", "start_pos": 4, "end_pos": 9}, {"label_type": "SideEff", "start_pos": 26, "end_pos": 30}, {"label_type": "Level", "start_pos": 47, "end_pos": 49}, {"label_type": "SideEff", "start_pos": 49, "end_pos": 52}, {"label_type": "Drug", "start_pos": 41, "end_pos": 46}, {"label_type": "Level", "start_pos": 24, "end_pos": 26}]}
{"originalText": "尤其是对于那些_体积相对较大的占位,以期减少假阴性结果的发生而减少因误_诊带来的致命危害._总之,老年肾上腺疾病有其不典型性和特殊性,由于缺乏_足够的重视和认识,在临床工作中常常会被忽视._老年人作为_当今社会一个重要的群体,理应被给予更多的关注._对老年肾_上腺疾病发病特点的深入了解,必能使更多患者从中受益,使_其获得更加及时有效的治疗,避免延误病情._每位医务工作者_更应在日常工作中注意数据的总结整理,对于未能确诊的病例_加强随访,从点滴做起切实提高老年肾上腺疾病的诊疗水平._", "entities": [{"label_type": "Anatomy", "start_pos": 128, "end_pos": 132}, {"label_type": "Anatomy", "start_pos": 231, "end_pos": 234}, {"label_type": "Anatomy", "start_pos": 51, "end_pos": 54}]}
{"originalText": "并逐步建立指南._参与本共识制定单位及人员(按姓氏拼音排序):苏州_大学附属儿童医院(陈临琪);福州儿童医院(陈瑞敏);第四_军医大学西京医院儿科(成胜权);成都市妇女儿童医院_(程昕然);哈尔滨医科大学附属第一医院儿科(崔岚巍);南_方医科大学附属深圳妇幼保健院儿科(董国庆);上海交通_大学附属瑞金医院儿科(董治亚);中山大学附属第一医院_儿科(杜敏联、李燕虹);浙江大学医学院附属儿童医院_(傅君芬、吴蔚);首都医科大学附属北京儿童医院(巩纯秀、_吴迪);上海交通大学医学院附属新华医院儿科(顾学范、_叶军);军事医学科学院附属医院儿科(何玺玉);广州市妇_女儿童医疗中心_(刘丽、黄永兰);山东省立医院儿科_(李桂梅);首都儿科研究所(李辉);上海交通大学附属儿童_医院(李嫔);青岛大学附属医院儿科(李堂);云南省第一人_民医院儿科(李利);浙江大学附属第一医院儿科(梁黎、_王春林);中山大学孙≥仙纪念医院儿科(梁立阳);华中科_技大学同济医学院附属同济医院儿科(罗小平、梁雁);天津_医科大学总医院儿科_(刘戈力);复旦大学儿科医院_(罗飞宏);新疆医科大学第一附属医院儿科(米热古丽·_买_买提);北京协和", "entities": []}
{"originalText": "推测_血清_Mir-217_升高参与了糖尿病肾病的发生和发展._Sirt1_是_NAD+依赖的去乙酰化酶,通过维持肾小_球屏障功能、抗纤维化、抗氧化应激、调节线粒体功能_等在肾脏起保护作用[22]._本研究发现,2_型糖尿病患_者血清_Sirt1_水平显著低于对照组,随着尿白蛋白升_高,Sirt1_水平逐渐下降._相关分析提示,_Sirt1_与_Ln(ACR)呈负相关,且多元逐步回归分析发现_Sirt1_是_ACR_的独立影响因素,提示血清_Sirt1_降低可能参与糖_尿病肾病的发生和发展._高糖诱导_HIF-1α_水平升高,进而促进肾脏纤维_化[23]._不成熟的异常血管生成是糖尿病肾病的发病_机制之一,高糖条件下,高表达的_HIF-1α_刺激其下游_VEGF_水平升高,从而诱导新生血管的形成,进而促进_糖尿病肾病的发生发展[24]._本研究观察到血清_HIF-1α_及_VEGF_水平显著高_于对照组,随着尿白蛋白升高,HIF-1α_及_VEGF_水平_逐渐升高._相关分析发现,HIF-1α、VEGF_与_Ln(ACR)_呈正相关,", "entities": [{"label_type": "Disease", "start_pos": 106, "end_pos": 112}, {"label_type": "Disease", "start_pos": 19, "end_pos": 24}, {"label_type": "Disease", "start_pos": 235, "end_pos": 241}, {"label_type": "Disease", "start_pos": 293, "end_pos": 298}, {"label_type": "Disease", "start_pos": 358, "end_pos": 363}, {"label_type": "Test", "start_pos": 136, "end_pos": 140}, {"label_type": "Test", "start_pos": 410, "end_pos": 414}, {"label_type": "Test", "start_pos": 177, "end_pos": 180}, {"label_type": "Test", "start_pos": 206, "end_pos": 209}, {"label_type": "Test", "start_pos": 464, "end_pos": 467}, {"label_type": "Reason", "start_pos": 6, "end_pos": 13}, {"label_type": "Test", "start_pos": 32, "end_pos": 37}, {"label_type": "Anatomy", "start_pos": 57, "end_pos": 61}, {"label_type": "Anatomy", "start_pos": 87, "end_pos": 89}, {"label_type": "Test", "start_pos": 118, "end_pos": 123}, {"label_type": "Test", "start_pos": 144, "end_pos": 149}, {"label_type": "Test", "start_pos": 166, "end_pos": 171}, {"label_type": "Test", "start_pos": 198, "end_pos": 203}, {"label_type": "Test", "start_pos": 223, "end_pos": 228}, {"label_type": "Test", "start_pos": 254, "end_pos": 260}, {"label_type": "Anatomy", "start_pos": 270, "end_pos": 272}, {"label_type": "Reason", "start_pos": 286, "end_pos": 292}, {"label_type": "Test", "start_pos": 318, "end_pos": 324}, {"label_type": "Test", "start_pos": 331, "end_pos": 335}, {"label_type": "Test", "start_pos": 383, "end_pos": 389}, {"label_type": "Test", "start_pos": 392, "end_pos": 396}, {"label_type": "Test", "start_pos": 417, "end_pos": 423}, {"label_type": "Test", "start_pos": 426, "end_pos": 430}, {"label_type": "Test", "start_pos": 447, "end_pos": 453}, {"label_type": "Test", "start_pos": 454, "end_pos": 458}]}
{"originalText": "正常人群中_TG_仅与_DI30_呈负相关,而_T2DM_中_TG_与_DI30、DI120_呈负相关,提示_TG_对_β_细胞的脂毒性作_用主要表现在_T2DM_中,并且主要影响胰岛素的早相分泌和总_体分泌,造成这一差异的原因可能是_T2DM_血清_TG_高于正常_人群._我们推测_T2DM_血清高水平的_TG_异位蓄积在这些患者_的胰岛内,影响胰岛内糖的利用和氧化,胰岛素分泌受损._胆固醇通过影响_β_细胞内葡萄糖激酶活性、细胞膜上脂质_筏的结构和诱导_β_细胞凋亡等途径影响胰岛素的分泌._本研_究发现在正常人群中,TC_与_DI30、DI120_呈负相关,而在_T2DM_中_TC_与_DI0、DI30、DI120_均呈负相关,提示_TC_在正常人群及_T2DM_中对_β_细胞的脂毒性作用相似,主要影响胰岛素的早相_分泌及总体分泌._我们推测循环中过多的_TC_一方面通过胰岛_表面相关受体进入胰岛内,引起胰岛内胆固醇蓄积,降低葡萄_糖激酶活性,诱导_β_细胞凋亡,减少胰岛素分泌,另一方面循环_中过多的_TC_蓄积在_β_细胞膜上,改变脂质筏的结构,影响分泌_胰岛素的囊泡胞吐过程,", "entities": [{"label_type": "Disease", "start_pos": 24, "end_pos": 28}, {"label_type": "Disease", "start_pos": 77, "end_pos": 81}, {"label_type": "Disease", "start_pos": 118, "end_pos": 122}, {"label_type": "Disease", "start_pos": 143, "end_pos": 147}, {"label_type": "Disease", "start_pos": 287, "end_pos": 291}, {"label_type": "Disease", "start_pos": 333, "end_pos": 337}, {"label_type": "Test", "start_pos": 263, "end_pos": 265}, {"label_type": "Test", "start_pos": 294, "end_pos": 296}, {"label_type": "Test", "start_pos": 323, "end_pos": 325}, {"label_type": "Test", "start_pos": 6, "end_pos": 8}, {"label_type": "Test", "start_pos": 31, "end_pos": 33}, {"label_type": "Test", "start_pos": 55, "end_pos": 57}, {"label_type": "Test", "start_pos": 126, "end_pos": 128}, {"label_type": "Test", "start_pos": 155, "end_pos": 157}, {"label_type": "Anatomy", "start_pos": 60, "end_pos": 64}, {"label_type": "Anatomy", "start_pos": 203, "end_pos": 207}, {"label_type": "Anatomy", "start_pos": 231, "end_pos": 235}, {"label_type": "Anatomy", "start_pos": 341, "end_pos": 345}, {"label_type": "Anatomy", "start_pos": 433, "end_pos": 437}, {"label_type": "Anatomy", "start_pos": 467, "end_pos": 471}, {"label_type": "Test", "start_pos": 12, "end_pos": 16}, {"label_type": "Test", "start_pos": 36, "end_pos": 40}, {"label_type": "Test", "start_pos": 41, "end_pos": 46}, {"label_type": "Anatomy", "start_pos": 90, "end_pos": 93}, {"label_type": "Anatomy", "start_pos": 169, "end_pos": 171}, {"label_type": "Anatomy", "start_pos": 242, "end_pos": 245}, {"label_type": "Anatomy", "start_pos": 175, "end_pos": 177}, {"label_type": "Anatomy", "start_pos": 186, "end_pos": 189}, {"label_type": "Anatomy", "start_pos": 195, "end_pos": 198}, {"label_type": "Anatomy", "start_pos": 208, "end_pos": 213}, {"label_type": "Anatomy", "start_pos": 216, "end_pos": 219}, {"label_type": "Anatomy", "start_pos": 220, "end_pos": 224}, {"label_type": "Test", "start_pos": 268, "end_pos": 272}, {"label_type": "Test", "start_pos": 273, "end_pos": 278}, {"label_type": "Test", "start_pos": 299, "end_pos": 302}, {"label_type": "Test", "start_pos": 303, "end_pos": 307}, {"label_type": "Test", "start_pos": 308, "end_pos": 313}, {"label_type": "Anatomy", "start_pos": 358, "end_pos": 361}, {"label_type": "Anatomy", "start_pos": 393, "end_pos": 402}, {"label_type": "Anatomy", "start_pos": 404, "end_pos": 406}, {"label_type": "Anatomy", "start_pos": 410, "end_pos": 412}, {"label_type": "Anatomy", "start_pos": 421, "end_pos": 427}, {"label_type": "Anatomy", "start_pos": 442, "end_pos": 445}, {"label_type": "Anatomy", "start_pos": 413, "end_pos": 416}, {"label_type": "Anatomy", "start_pos": 488, "end_pos": 491}, {"label_type": "Anatomy", "start_pos": 476, "end_pos": 479}, {"label_type": "Anatomy", "start_pos": 385, "end_pos": 387}, {"label_type": "Anatomy", "start_pos": 460, "end_pos": 462}]}
{"originalText": "对于强的松(60_mg_/_d_起始)_约_60%患者症状较前缓解._环孢素_A_最常见的不良反应为剂_量依赖的肝肾毒性、牙龈增生,偶有肌酐轻度升高._此外,亦可_见克雷伯氏肺炎、肌酐不可逆升高及血压一过性升高等._(d)_利妥昔单抗:早前,利妥昔单抗被认为是活动性_GO_患_者静脉_GCs_治疗无效时的首选._随着研究的深入,利妥昔单抗_治疗中重度活动性_GO_的资料层出不穷._2_项小样本临床试验_得出结论相悖的结果._Salvia_等[4]_发现,与静脉_GCs_组比较,_利妥昔单抗组_GO_进入非活动期的比例明显增加;并且,利妥_昔单抗组治疗后_GO_未再呈现活动状态,而_GCs_静脉给药组约_有_31%的患者复现活动性;此外,利妥昔单抗组在改善眼球运_动及_QoL_方面稍优于静脉_GCs._源自_Stan_等[5]的数据却显示,_利妥昔单抗组与安慰剂组在治疗_GO_上并无明显差异._2_例治_疗前无明显或即将发生甲状腺功能异常相关性视神经病变_(DON)的患者,在利妥昔单抗治疗后出现_DON._两项研究结_果大相径庭的原因仍难以解释,可能与后者的病程较长有关._由于存在争议,目前,", "entities": [{"label_type": "Drug", "start_pos": 112, "end_pos": 117}, {"label_type": "Drug", "start_pos": 121, "end_pos": 126}, {"label_type": "Drug", "start_pos": 165, "end_pos": 170}, {"label_type": "Drug", "start_pos": 242, "end_pos": 247}, {"label_type": "Drug", "start_pos": 269, "end_pos": 275}, {"label_type": "Drug", "start_pos": 322, "end_pos": 327}, {"label_type": "Drug", "start_pos": 375, "end_pos": 380}, {"label_type": "Drug", "start_pos": 443, "end_pos": 448}, {"label_type": "Drug", "start_pos": 35, "end_pos": 40}, {"label_type": "Drug", "start_pos": 2, "end_pos": 5}, {"label_type": "Amount", "start_pos": 6, "end_pos": 15}, {"label_type": "SideEff", "start_pos": 50, "end_pos": 60}, {"label_type": "SideEff", "start_pos": 61, "end_pos": 65}, {"label_type": "SideEff", "start_pos": 83, "end_pos": 89}, {"label_type": "Method", "start_pos": 140, "end_pos": 142}, {"label_type": "Drug", "start_pos": 143, "end_pos": 146}, {"label_type": "Level", "start_pos": 173, "end_pos": 176}, {"label_type": "Method", "start_pos": 230, "end_pos": 232}, {"label_type": "Drug", "start_pos": 233, "end_pos": 236}, {"label_type": "Disease", "start_pos": 249, "end_pos": 251}, {"label_type": "Disease", "start_pos": 280, "end_pos": 282}, {"label_type": "Drug", "start_pos": 294, "end_pos": 297}, {"label_type": "Method", "start_pos": 347, "end_pos": 349}, {"label_type": "Drug", "start_pos": 350, "end_pos": 353}, {"label_type": "Disease", "start_pos": 390, "end_pos": 392}, {"label_type": "Disease", "start_pos": 417, "end_pos": 432}, {"label_type": "Disease", "start_pos": 434, "end_pos": 437}, {"label_type": "Disease", "start_pos": 454, "end_pos": 457}, {"label_type": "Level", "start_pos": 254, "end_pos": 258}, {"label_type": "Test", "start_pos": 338, "end_pos": 341}, {"label_type": "SideEff", "start_pos": 68, "end_pos": 74}, {"label_type": "SideEff", "start_pos": 90, "end_pos": 97}, {"label_type": "SideEff", "start_pos": 98, "end_pos": 105}, {"label_type": "Disease", "start_pos": 130, "end_pos": 136}, {"label_type": "Disease", "start_pos": 176, "end_pos": 182}, {"label_type": "Method", "start_pos": 298, "end_pos": 302}]}
{"originalText": "主要作用是拮抗_CDK_活性[16],而细_胞周期由两者结合成周期素_/_CDK_复合物来触发,该_复合物是细胞周期的核心调控分子._在人类中,有两_种_Cdc14_同源物:Hcdc14A_和_Hcdc14B._Hcdc14A_在_人类不同组织中表达有所差异,在大脑、心脏及小肠及_骨骼肌中呈高表达,其它组织中则为中低表达._鉴于_Hcdc14A_在细胞周期中的核心地位及其重_要性,因此本研究的主要靶点是_Hcdc14A._Hcdc14A_与其他周期蛋白关系密切,细胞周期调节机制的核心_是周期素_/_CDK_表达与活性的调控._周期素_B_主要参_与调控_G2_期向_M_期的过渡,周期素_D_与周期素_E_可_共同促进_G1_期向_S_期转换,而_p53_的作用是使细胞_阻滞在_G1_/_S_和_G2_/_M_期,从而阻滞细胞周期并诱导_细胞凋亡._因此本研究同时观察了高糖、高_FFA_和低_氧联合刺激对_HBVEC_中_Hcdc14A_及其他相关周期蛋_白表达的影响._结果提示,高糖、高_FFA_及低氧均可_下调_Hcdc14A_表达,同时下调周期素_B、周期素_D_和_周期素_E_表达,", "entities": [{"label_type": "Anatomy", "start_pos": 131, "end_pos": 133}, {"label_type": "Anatomy", "start_pos": 134, "end_pos": 136}, {"label_type": "Anatomy", "start_pos": 137, "end_pos": 139}, {"label_type": "Anatomy", "start_pos": 141, "end_pos": 144}, {"label_type": "Anatomy", "start_pos": 327, "end_pos": 330}, {"label_type": "Reason", "start_pos": 456, "end_pos": 458}, {"label_type": "Anatomy", "start_pos": 464, "end_pos": 471}, {"label_type": "Anatomy", "start_pos": 408, "end_pos": 413}, {"label_type": "Anatomy", "start_pos": 416, "end_pos": 423}, {"label_type": "Anatomy", "start_pos": 213, "end_pos": 220}, {"label_type": "Anatomy", "start_pos": 166, "end_pos": 173}, {"label_type": "Anatomy", "start_pos": 204, "end_pos": 211}, {"label_type": "Anatomy", "start_pos": 87, "end_pos": 94}, {"label_type": "Anatomy", "start_pos": 97, "end_pos": 104}, {"label_type": "Anatomy", "start_pos": 77, "end_pos": 82}, {"label_type": "Anatomy", "start_pos": 106, "end_pos": 113}, {"label_type": "Reason", "start_pos": 389, "end_pos": 391}, {"label_type": "Reason", "start_pos": 399, "end_pos": 402}, {"label_type": "Anatomy", "start_pos": 266, "end_pos": 271}, {"label_type": "Anatomy", "start_pos": 8, "end_pos": 11}, {"label_type": "Anatomy", "start_pos": 31, "end_pos": 44}, {"label_type": "Anatomy", "start_pos": 246, "end_pos": 255}, {"label_type": "Anatomy", "start_pos": 293, "end_pos": 298}, {"label_type": "Anatomy", "start_pos": 300, "end_pos": 305}, {"label_type": "Reason", "start_pos": 392, "end_pos": 397}, {"label_type": "Reason", "start_pos": 446, "end_pos": 448}, {"label_type": "Reason", "start_pos": 449, "end_pos": 454}, {"label_type": "Test", "start_pos": 479, "end_pos": 484}, {"label_type": "Test", "start_pos": 485, "end_pos": 490}, {"label_type": "Test", "start_pos": 493, "end_pos": 498}]}
{"originalText": "移除_XBP-1_中的一段由_26_个核苷酸组成的非常规内含子,使无活_性的_XBP-1_前体_mRNA_分子剪接为有活性的_XBP-_1s[6],进而增加分子伴侣蛋白的产生,促进未折叠蛋白_反应(_unfolded_protein_respons,UPR),对_ERs_进行应_答._当内质网长期处于应激状态或_ERs_严重得不到_缓解时,会启动细胞程序性死亡,即细胞凋亡._IRE1α_可能是诱导细胞凋亡过程中关键的信号分子,可通过_其激酶的作用,结合肿瘤坏死因子受体相关因子_2_(TNF_receptor_associated_factor_2,TRAF2),并与凋亡信_号调节激酶_(_TNF-dependent_apoptosis-signaling_kinase_1,ASK1)_共同形成_TRAF2-ASK1-JNK_复合体,激活_JNK_通路,JNK_是一种丝裂原活化蛋白激酶(mitogen-_activated_protein_kinase,_MAPK)_[7],一方面可以调节凋_亡相关基因_Bcl-2,甚至直接激活_Bcl_家族中_Bax_基因_促进凋亡,另一方面,", "entities": [{"label_type": "Anatomy", "start_pos": 228, "end_pos": 242}, {"label_type": "Test", "start_pos": 374, "end_pos": 377}, {"label_type": "Anatomy", "start_pos": 458, "end_pos": 463}, {"label_type": "Anatomy", "start_pos": 479, "end_pos": 482}, {"label_type": "Anatomy", "start_pos": 144, "end_pos": 147}, {"label_type": "Disease", "start_pos": 157, "end_pos": 160}, {"label_type": "Disease", "start_pos": 183, "end_pos": 187}, {"label_type": "Disease", "start_pos": 200, "end_pos": 204}, {"label_type": "Anatomy", "start_pos": 3, "end_pos": 8}, {"label_type": "Anatomy", "start_pos": 39, "end_pos": 44}, {"label_type": "Anatomy", "start_pos": 78, "end_pos": 84}, {"label_type": "Anatomy", "start_pos": 63, "end_pos": 70}, {"label_type": "Anatomy", "start_pos": 286, "end_pos": 295}, {"label_type": "Anatomy", "start_pos": 388, "end_pos": 397}, {"label_type": "Anatomy", "start_pos": 471, "end_pos": 474}, {"label_type": "Anatomy", "start_pos": 45, "end_pos": 52}, {"label_type": "Anatomy", "start_pos": 381, "end_pos": 384}]}
